Esophageal Cancer
Conditions
Keywords
positron emission tomography, cervical lymphatic metastasis
Brief summary
Esophageal cancer is the eighth most common cancer around the world, with more than 450000 new cases per year. Esophagectomy with radical lymphadenectomy (2-field lymphadenectomy) is the mainstay of treatment in many countries for patients with esophageal cancer. To improve the survival, 3-field lymphadenectomy combined with cervical lymphadenectomy was started in 1980s. More potential positive lymph nodes were found during more extended lymphadenectomy, offering more accurate TNM staging, affecting consequent treatment. However，3-field-lymphadenectomy was associated with increased surgical morbidity and mortality. Positron emission tomography (PET) is used for detecting distant metastases and lymphatic involvement. The aim of the study is to evaluate the role of PET in predicting cervical lymph metastases of patients with thoracic esophageal squamous cell carcinoma, and to determine if investigators can use PET to guide future cervical lymphadenectomy. (Eastern Cooperative Thoracic Oncology Projects 2003, ECTOP-2003)
Detailed description
From June, 2018, a total of 110 patients with thoracic esophageal carcinoma will be recruited in 4 hospital in China. Participants with resectable esophageal cancer will have PET/CT scan before three-field lymphadenectomy. Lymph nodes will be recored according to the anatomy site. Lymph nodes metastasis diagnosed by PET/CT and by postoperation pathological examination will be compared to evaluate the role of PET/CT in guiding the extent of lymphadenecomy and surgical approach.
Interventions
DIAGNOSTIC_TESTpositron emission tomography
patients who had esophagectomy with 3-field lymphadenectomy underwent examination of positron emission tomography prior to surgery within 2 weeks.
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically proven esophageal cancer 2. Resectable cT1-T3/N0-N1 thoracic，operable esophageal lesion. Staging investigations including esophagogastroscopy, chest and abdominal CT scan, and barium swallow 3. Karnofsky performance status greater than or equal to 80% 4. Acceptable pulmonary and cardiac function. 5. Acceptable hepatic, renal and bone marrow function
Exclusion criteria
1. Low performance status(Karnofsky score \<80%) 2. Past history of malignancy 3. Unresectable advanced disease(T4 or M1a,M1b) 4. Patients with any other serious underlying medical condition that would impair the ability of the patient to receive or comply with protocol treatment 5. Medically unfit for surgical resection 6. Pulmonary reserve inadequate to undergo thoracotomy and extensive mediastinal lymphadenectomy. 7. A significant history of unstable cardiovascular disease that in the opinion of the treating physician should preclude the patient from protocol treatment. 8. Uncontrolled diabetes mellitus or uncontrolled infection, including HIV or interstitial pneumonia or interstitial fibrosis. 9. Significant psychiatric illness that would interfere with patient compliance 10. Severe hepatic cirrhosis or with serious renal disease unacceptable for surgery 11. Salvage surgery after definitive chemoradiotherapy 12. Patients have neoadjuvant chemoradiotherapy 13. Above the age of 80 years 14. Unreliable for follow up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cervical lymph node metastasis | Decembear 2018 | postoperative pathological examination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| mediastinal and abdonimal lymph nodes metastasis | Novermber 2018 | postoperative pathological examination |
| postoperative complications | March 2019 | surgical morbidity and mortality |
| diseases-free survival | November 2021 | from the time of surgery to the time of first recurrence or death |
Countries
China
Outcome results
None listed